Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company headquartered in London, United Kingdom. The enterprise develops, manufactures, and markets a broad portfolio of generic, branded, and injectable medications. Its product divisions cover anti-infectives, central nervous system treatments, oncology medicines, respiratory products, and pain management therapeutics. Principal revenue is derived from direct pharmaceutical sales to hospitals, pharmacies, healthcare institutions, and wholesale distributors. The firm maintains commercial operations across the Middle East, North Africa, the United States, and Europe. Hikma Pharmaceuticals PLC is publicly traded on the London Stock Exchange.
27 of the funds FundTelligence covers report a position in Hikma Pharmaceuticals.
- Legal name
- Hikma Pharmaceuticals Plc
- Sector
- Health Care
- Country
- United Kingdom
- Funds holding it
- 27
Funds holding Hikma Pharmaceuticals
- Polar Capital Healthcare Discovery Fund — Polar Capital · 2.6 % (largest positions only, October 2026)
- Schroder ISF European Dividend Maximiser — Schroders · 1.06 % (full portfolio disclosed, June 2026)
- Schroder ISF Healthcare Innovation — Schroders · 0.58 % (full portfolio disclosed, June 2026)
- Handelsbanken Global Bærekraft — Handelsbanken · 0.44 % (full portfolio disclosed, October 2026)
- Nordea Discretionary Global Equity — Nordea Funds · 0.11 % (full portfolio disclosed, July 2026)
- Nordea PM Globale Aktier Strategi — Nordea Funds · 0.1 % (full portfolio disclosed, July 2026)
- Nordea Plan Offensiv — Nordea Funds · 0.08 % (full portfolio disclosed, September 2026)
- Nordea Internationale aktier — Nordea Funds · 0.07 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 27 funds holding it.